Primerica Inc Dossier
|
SectorFinancials IndustryInsurance - Life Beta (adjusted)0.91 Intrinsic Value $274.22median of 2 methodsbased on filings through 30 Jun 2026 Market Price $274.72Price as of 1 Oct 2026 Near fair valueIntrinsic value is 0% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $8.5B Enterprise Value $9.6B Shares Outstanding 31M diluted Next Earnings Date4 Nov 2026 Last ex-dividend21 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Primerica's second-quarter 2026 evidence is balanced. Investment and Savings Products delivered record sales, positive net inflows, sharply higher client asset values, and strong segment growth, while the established Term Life book continued to provide recurring premiums and cash generation. Offsetting those strengths, the life-licensed sales force declined 3%, newly licensed representatives declined 15%, policies issued declined 12%, and Term Life pre-tax income declined 4%. The resulting stance is Hold pending evidence that licensing and policy production stabilize without sacrificing the investment-business momentum. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$276.00 Mean target$321.17 High · most bullish analyst$370.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $276.0024% Continued contraction in the licensed sales force and weak licensing conversion drive further declines in policies issued. A market decline or weaker client demand reverses investment-product flows and reduces client asset values, weakening asset-based commissions at the same time that Term Life expenses remain elevated. Base CaseCentral scenario $321.1757% Matches the consensus meanInvestment and Savings Products growth continues to offset subdued Term Life new-business production, while the large in-force insurance block supports stable premiums and cash generation. Capital remains ample for dividends and repurchases. Bull CaseUpside scenario $370.0019% Investment-product demand remains strong, positive flows and favorable product mix sustain growth in asset-based revenue, and recruiting converts into more newly licensed representatives. Stabilization of the life-licensed sales force and renewed policy growth would restore a second earnings-growth engine alongside the investment business. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |